Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Cryoport $403 million notes offering and concurrent $249 million stock offering
The company issued 0.75% convertible senior notes due 2026 and sold shares in a registered direct offering
Aligos Therapeutics $75 million at-the-market offering
The company issued common stock in the SEC-registered at-the-market offering
Option Care Health $500 million notes offering
The company issued high-yield senior notes due 2029 in the Rule 144A / Regulation S offering
IVERIC bio $173.4 million stock offering
We advised the underwriters on the SEC-registered equity offering
MicroTech Medical HK$1.82 billion IPO
We advised MicroTech Medical on its IPO and HKEX listing
Abbisko HK$1.7 billion IPO
We advised Abbisko on its IPO and HKEX listing
PHC Holdings ¥82.6 billion IPO
We advised the international managers in connection with the IPO and TSE listing
Supernus Pharmaceuticals $450 million acquisition of Adamas Pharmaceuticals
We are advising Lazard as financial adviser to Adamas
Securities litigation victory for Synergy Pharmaceuticals officers and directors
We secured a total victory for the clients, with all claims against them dismissed
Inventiva at-the-market offering
We advised the sales agent on the SEC-registered offering of ADSs